Feedback on proposal to amend access criteria for type 2 diabetes medicines

Overview

We sought your feedback on a proposal for people living with Type 2 diabetes and at risk of cardio-renal complications. We are proposing to widen access to:

• empagliflozin (Jardiance)
• empagliflozin with metformin (Jardiamet)
• dulaglutide (Trulicity)
• liraglutide (Victoza)

What happens next

Pharmac has received a significant volume feedback to this proposal.

We will take time to consider it thoroughly. The final proposal will be submitted to the Pharmac Board to review and make a final decision. 

We will publish our final decision on the Pharmac website.

Pharmac's decisions